5-fluorouracil, adriamycin, and mitomycin-c (fam) combination chemotherapy in the treatment of advanced gastric cancer

摘要: Thirty-six patients with advanced measurable gastric cancer were treated a new combination chemotherapy program consisting of 5-fluorouracil, Adriamycin and mitomycin-C (FAM). Fifty percent achieved an objective partial response. The median duration remission was 9.5 months the survival for responding 13.5 months, 2 remaining alive at 14 26 months. nonresponding 3.0 all dead by 6 after initiation therapy. 36 FAM 5.5 An analysis possible prognostic variables including initial performance status, resectability primary tumor histologic differentiation neoplasm failed to account differences in patient response survival. regimen well tolerated, produced only moderate bone marrow suppression. These results demonstrate that some can be effectively palliated chemotherapy. Phase III trials are warranted assess effect on cancer.